Navigating Tensions when Dermatologists Change Jobs: Who Should Manage Biopsy Results [0.03%]
dermatologist离职带来的病理资料管理问题怎么办？
Sowmya Ravi,Timothy Klufas,Albert E Zhou et al.
Sowmya Ravi et al.
Grace X Li,Deshan F Sebaratnam
Grace X Li
Systemic immune profiling identifies elevated MRGPRX2 with a distinct inflammatory signature in chronic pruritus of unknown origin [0.03%]
系统性免疫谱分析发现慢性原因不明瘙痒症中MRGPRX2升高并具有特定的炎症特征
Yagiz Matthew Akiska,Aaron Bao,Davies Gage et al.
Yagiz Matthew Akiska et al.
No association between low-dose oral minoxidil and tachycardia in a large retrospective cohort study of non-scarring alopecia patients [0.03%]
一项有关非瘢痕性脱发患者的大型回顾队列研究未发现低剂量口服密酮和心动过速之间存在关联
Zachary J K Neubauer,Henry I Lipner,Shari R Lipner
Zachary J K Neubauer
Toenail matrix graft reconstruction for pediatric fingernail longitudinal melanonychia > 3 mm: Evaluation of the method in a series of 7 cases [0.03%]
儿童纵向黑甲病指甲矩阵移植重建术的评估——7例临床报道
Rong Zhou,Xiaofei Tian,Lin Qiu et al.
Rong Zhou et al.
Comorbidity burden and real-world treatment patterns of neuropathic pruritus: a retrospective cohort study [0.03%]
共病负担和特发性瘙痒症的现实世界治疗模式：回顾队列研究
Viviane Liao,Yagiz Matthew Akiska,Elizabeth Wang et al.
Viviane Liao et al.
Dermatologic Adverse Events Associated with Gamma Secretase Inhibitor Nirogacestat: A Retrospective Multicenter Cohort Study [0.03%]
尼罗呱色替(γ-分泌酶抑制剂)引起的皮肤不良反应的回顾性多中心队列研究
Grant J Riew,Lauren M Guggina,Federico Repetto et al.
Grant J Riew et al.
Type 2 Immunity Links Eczematous and Lichenoid Eruptions Caused by Immune Checkpoint Inhibitors [0.03%]
2型免疫反应连接免疫检查点抑制剂引起的湿疹和类扁平苔藓皮疹
Marjan Azin,Parisa Farokh,Alexander McGarry et al.
Marjan Azin et al.
Background: Cutaneous immune-related adverse events (cirAEs) induced by immune checkpoint inhibitor (ICI) therapy share clinical features with spontaneous inflammatory dermatoses. However, the exact immunopathogenesis of ...
A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52) [0.03%]
BAT2206（乌司奴单抗类似药）与原研乌司奴单抗治疗中重度斑块状银屑病III期、随机、双盲、头对头临床研究：第2个治疗期结果（第28周至第52周）
Xiaoyong Man,Katya Zaharieva,Grażyna Pulka et al.
Xiaoyong Man et al.
Background: BAT2206 is being developed as a ustekinumab (UST) biosimilar. Objectives: Equivalent efficacy and comparable safety results...
A real-world analysis of adverse event signals of cognitive and communication disorder in patients treated with Janus kinase inhibitors based on the FAERS database [0.03%]
基于FAERS数据库的 janus 激酶抑制剂治疗患者认知和沟通障碍不良事件信号的实时分析
Jieyu Lin,Yufan Cheng,Ling Chen et al.
Jieyu Lin et al.